Ann: MSB Q1 Financial Results and Operational Highlights, page-37

Few comments on CLBP absence. They should have put a note in, but this is a quarterly operational and financial update. Its likely simply nothing much happend in CLBP. They'd had talks with the FDA before. Preusmably they did not progress those in the quarter, nor were there any new research insights.

Apologies for stating the obvious, but another shorter started yet another thread on MSB's future - this so clearly the thread to discuss. Its pretty clear we are sat on a ticking call option, that SI just extended the expiration on with the debt deal. It's now all down to OTAT.

SHorting down here is risky. Its a simple array of binary event that holds $1.75 of potential ulimate gain for shorters, each time MSB gets a set back it goes down....but big result..... If MSB gets the nod on potency assays on GVHD, that opens the door on CHF, ARDS and CLBP and many other potential applications down the line. Novartis likely finalise partnership if OTAT is positive. We know where this stock went before. The upside for longs is so much more potentially beneficial.

I am happy to have a big punt on one of the most shorted stocks on the ASX. SI just extended the expiry on the many call options that makes MSB one big call option. Going back to late 2020 when we had four potential successes out there, I had a range of approx. 30-70% probablitiies on those possibilities and the stock was trading $5. My probabilities are not dissimilar now at $1.75. Its a no brainer from an objective statistical perspective.